Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers.
Sign Up to like & getrecommendations! Published in 2017 at "Thrombosis and haemostasis"
DOI: 10.1160/th16-05-0385
Abstract: Idarucizumab, a humanised monoclonal antibody fragment, binds dabigatran with high affinity and immediately, completely and sustainably reverses dabigatran-induced changes on blood coagulation. The present analysis focuses on the evaluation of potential procoagulant properties of idarucizumab… read more here.
Keywords: idarucizumab procoagulant; infusion; procoagulant effects; thrombosis ... See more keywords